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HEALTH LITERACY-ASSOCIATED DIFFERENCES OF MEDICATION USE 
IN CROHN’S DISEASE 
ANZHU YU 
ABSTRACT 
Purpose: The aim of this study was to explore a difference in medication use 
(defined by medication selection and medication self-discontinuation) between patients 
with limited and adequate health literacy. This study also investigated whether the 
association between medication use and clinical remission of CD was different across the 
health literacy spectrum.  
Methods: A cross-sectional study was conducted by analyzing an existing dataset 
from the IBD Health Literacy study in the Department of Gastroenterology at Boston 
Medical Center (BMC). Among 61 patients who were enrolled, 26 had limited health 
literacy and 35 had adequate health literacy. Medication use was defined by medication 
selection and medication self-discontinuation. Medication selection was further defined 
as whether patients with monotherapy were on one of the following medications 
including 5-ASAs, immunomodulators (including thiopurines and methotrexate), 
biologics and prednisone; medication self-discontinuation was further defined as whether 
patients had ever discontinued medications (including thiopurines and biologics) without 
physician recommendation. Harvey Bradshaw Index score was the assessment of clinical 
remission of CD. Newest Vital Sign scores were applied to assess health literacy.  
Results: The odds ratios for patients who were on 5-ASAs and immune 
modulators (including thiopurines and methotrexate) monotherapy at the time of visit to 
  vi 
have limited health literacy, compared to patients who were on monotherapy of biologic 
agent, were 3.75 (95%CI (0.46-38.26), p = 0.22) and 1.25 (95%CI (0.13-9.67), p = 0.83), 
respectively. The odds ratio for those whoever self-discontinued any medications to have 
limited health literacy versus those who did not was 1.62 (95%CI (0.42-6.24), p = 0.48). 
The odds ratio for patients whoever self-discontinued any medications to be in clinical 
remission against those who did not was 0.46 (95%CI (0.1-1.85), p = 0.27). The odds 
ratio for associations between medication self-discontinuation and clinical remission 
were 0.6 (95%CI (0.06-4.58), p = 0.63) in patients with limited health literacy and 0.5 
(95%CI (0.06-4.62), p = 0.51) in patients with adequate health literacy. 
Conclusion: There were no differences of medication use between limited and 
adequate health literacy. The association between medication self-discontinuation and 
clinical remission of CD was indifferent across the health literacy levels. The results of 
this study provides a foundation for future studies on health literacy associated 
differences in CD populations and helps promote the effectiveness of treatment for CD 
by arousing more attention to different health literacy populations. 
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INTRODUCTION 
Crohn’s disease (CD) 
Crohn’s disease (CD) is an immune-mediated, chronic inflammatory intestinal 
condition with extra-intestinal manifestations. It is one of two primary disorders that are 
collectively termed inflammatory bowel disease (IBD).1 CD is characterized by relapsing 
transmural inflammation that can affect any part of the gastrointestinal (GI) tract from the 
mouth to the anus. The terminal ileum is the most frequently involved segment.1–3 In 
North America, the incidence rate ranges from 3.1-14.6 cases per 100,000 person-years 
for CD, with a prevalence of 26-199 cases per 100,000 persons.1,4 Epidemiological risk 
factors associated with CD include age between 15 and 30 years, Jewish descent, urban 
lifestyle, higher socioeconomic class, and a family history of the disorder.1 Other risk 
factors include genetic predispositions3, oral contraceptive use, and pre-existing 
immunodeficiency disorders such as chronic granulomatous disease and Wiskott-Aldrich 
syndrome.1  
 
The inflammatory processes of CD can evolve towards either a fibrostenotic 
obstructing pattern or a penetrating pattern (or “phenotype”) complicated by the 
formation of fistulas and abscesses. A fibrostenotic obstructing pattern is usually seen in 
ileocolitis when persistent inflammation has resulted in recurrent scarring of the intestinal 
wall and subsequently narrowing the intestinal lumen; a penetrating pattern develops 
when the inflammation affects all layers of the intestinal wall, leading to either a 
perforation (i.e. –leakage of bowel content into abdominal cavity) or a fistula (i.e. –
 2 
connection of one segment of bowel to another or even another organ).5 The disease 
phenotype at clinical presentation will impact prognosis and guide treatment.1 In 
addition, clinical manifestations will vary according to the location of the disease (Figure 
1).1  
 
Figure 1. Common locations of Crohn’s disease6 
 
 
Patients with ileocolitis more commonly present with chronic right lower 
quadrant abdominal pain and obstructive symptoms due to narrowing of the terminal 
ileum as it abuts the ileocecal valve. Less commonly, if the disease is complicated, these 
patients may develop leukocytosis and fevers that sometimes mimics an acute 
appenditis.1 Patients with more proximal small bowel involvement (jejunoileitis) 
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characteristically present with diarrhea, malabsorption, and steatorrhea, and are at 
greatest risk for malnutrition.1 Patients with Crohn’s disease that only involves the colon, 
Crohn’s colitis, typically present with bloody diarrhea, crampy abdominal pain and rectal 
urgency, sometimes with fecal incontinence. If the perianal region is involved, patients 
can develop strictures of the anal canal, perianal fistulae and abscesses.1 In addition to 
those complications described above, if untreated or refractory, CD can progress to result 
in bowel perforation, intra-abdominal and pelvic abscesses, partial or complete intestinal 
obstruction and massive hemorrhage from intestinal ulcerations.1  
 
Although the gold diagnostic standard for CD is endoscopy with biopsy, CD is a 
clinical diagnosis that integrates history, symptoms, laboratory findings, radiographic and 
histopathology features.1,2 CD shares a variety of features with many other diseases, in 
particular ulcerative colitis (UC), the other primary form of IBD.1 Approximately 15% of 
IBD does not have the characteristic appearance of either CD and UC; this is termed 
indeterminate colitis.1 Once a diagnosis of CD is established, phenotypes and disease 
activity should be assessed, according to Montreal classifications (Table 1), in order to 
help identify the most appropriate therapeutic regimen.2,7  
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Montreal Classification for Crohn’s Disease 
Age of Onset (A) 
[A1] Below 16 years old 
[A2] Between 17-40 years old 
[A3] >40 years old 
Disease Location (L) 
[L1] Ileal 
[L2] Colonic 
[L3] Ileocolonic 
[L4] Isolated upper disease modifier 
Disease Behavior (B) 
[B1] Non-stricturing, non-penetrating        
[B2] Stricturing 
[B3] Penetrating 
[p] Perianal disease modifier 
Table 1. Montreal classification for Crohn’s disease 
 
Clinical Remission of CD 
Patients with CD typically experience clinical disease remission and relapse 
throughout their lifetime. Periods of remission can last anywhere from a few days to 
years, and relapses can occur even with treatment. Factors that can trigger a flare-up 
include stress, missed medications, recent use of non-steroidal anti-inflammatory drugs 
(NSAIDs), and smoking.8 Clinical remission is defined by the complete absence of CD 
symptoms. Various scoring systems have been used to quantify the degree of clinical 
symptoms in patients with Crohn’s disease. For example, the Harvey Bradshaw Index 
(HBI) is a simple index of Crohn’s disease activity obtained by evaluating five aspects of 
disease: general well-being, abdominal pain, number of liquid or soft stools for the day 
prior to the visit, abdominal mass and complications.9,10  
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Medications in Current Use 
Treatment options for CD have become more complex as new medications have 
been developed. Major groups of medications indicated for the treatment of CD include: 
5-Aminosalicylates (5-ASA), immunomodulators (thiopurine derivatives and 
methotrexate (MTX)) “biologics” (manufactured antibodies against proteins that cause 
inflammation, i.e. -infliximab) and corticosteroids (i.e. - prednisone).  
  
Corticosteroids 
Corticosteroids are very effective in the short-term treatment of acute flares in 
patients with moderate to severe CD, but are not recommended as a maintenance 
therapy.11–13 Patients who respond well to corticosteroids typically notice a benefit within 
1-2 weeks and remain in remission as the steroids are tapered and discontinued.11 Those 
patients who do not respond to corticosteroid therapy will need a more intense 
medication, either an immunomodulator, biologic or a combination of the two.11  
 
5- Aminosalicylates (5-ASAs) (Mild Disease) 
Aminosalicylates work by inhibiting the cyclooxygenase and 5-lipoxygenase 
pathways of arachidonic acid metabolism, processes that generate numerous nonspecific 
inflammatory substances such as thromboxanes, leukotrienes, prostaglandins, free 
radicals and nitric oxide.12 While 5-ASA medications can be used first-line to induce 
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remission in mild (and in some cases moderate) CD, the evidence cannot point to a clear 
benefit of 5-ASA medications in CD patients who have achieved clinical remission.11,12  
 
Immune modulators: (Moderate Disease)  
6-Mercaptopurine (6-MP) and azathioprine (AZA) 
6-MP and AZA are thiopurine derivatives which impair purine biosynthesis and 
inhibit cell proliferation; they may also exhibit direct anti-inflammatory properties.11,12 
Both agents are used in patients with more moderate CD who are either refractory to or 
dependent on corticosteroids, as well as those who have recurrent flares of disease 
requiring repetitive courses of steroids.11,12,14 Therapeutic onset of 6-MP and AZA is 
about 12-17 weeks after initiation.14,15 Studies have shown improved rates of clinical 
remission when thiopurines are used in combination with biologics.14,16–18 Side effects of 
thiopurines include nausea, vomiting, dose-related bone marrow suppression, 
hepatotoxicity, and infections, etc.11 
 
Methotrexate (MTX) 
MTX was first recognized as cancer therapy because it blocked DNA synthesis 
and induced cell death by inhibiting dihydrofolate reductase, a key enzyme in pyramidine 
synthesis.11 Because MTX possessed immune modulating and anti-inflammatory 
properties, it was then introduced to treat autoimmune diseases such as rheumatoid 
arthritis and CD.11,12 MTX is currently recommended for induction treatment and 
maintenance therapy in moderate to severe Crohn’s disease. Time to therapeutic onset 
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may be more rapid with MTX than thiopurine derivatives.11,12,19 Parental administration 
(i.e. -intramuscular administration) is important in treating CD, particularly in patients 
with small bowel diseases whose drug absorption may be impaired.11,12  
 
Biologics: (Moderate to Severe Disease)  
Biologics refers to antibodies cultured in laboratories that can bind and block 
certain proteins, such as tumor necrosis factor-α (TNF-α), which promote inflammation 
in the intestines as well as other tissues and organs.20 The onset of therapeutic benefit 
from biologics may range from 6 to 14 weeks after initiation, though many experience a 
more rapid response.20 Infliximab (Remicade®) is one of the biologics that are intended 
for both induction and maintenance of remission in patients with moderate to severe CD.  
 
Infliximab (Remicade®) 
Infliximab is a chimeric monoclonal IgG1 antibody that binds to and neutralizes tumor 
necrosis factor-α (TNF-α), one of the principle cytokines that mediate the TH1 immune 
response to the inflammation of CD.11,12,21 Infliximab is used to treat moderate to severe 
CD, which includes disease that is steroid-dependent, steroid-refractory, failing to 
respond to other therapies or has penetrating complications.11,22–24 The combination of 
infliximab and thiopurine has been shown to be more effective than monotherapy for CD. 
Though similar evidence is not available for the combination of infliximab and MTX  
given similar properties of the medications, this combination is widely used in clinical 
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practice .11,23,25 Possible side effects of infliximab include fever, anaphylaxis, drug 
intolerance, respiratory infections and reactivation of tuberculosis.11,23  
 
Goals and Strategy of Therapy 
To date, no unique therapeutic target has been identified in CD. Therefore, current 
medical therapy seeks to dampen the generalized inflammatory response.11,12 Specific 
goals of treatment include controlling acute exacerbations of disease (i.e. –inducing 
remission), treating complications, preventing disease progression and maintaining 
remission.11 Although the goals of the treatment vary in each individual patient, the 
primary objective is to induce and maintain CD remission. The first goal is induction of 
CD remission, which refers to the control of inflammation and thus symptoms in acute 
active CD.20 Once CD remission is achieved, the long-term aim of managing CD is to 
maintain the remission.26 While most medications can be used for both induction and 
maintenance of CD remission, one clear exception is prednisone, which is only indicated 
for induction of remission due to various side effects associated with long-term use (i.e.-
moon face, buffalo hump, truncal obesity, infections, osteoporosis, hypertension, 
hyperglycemia, and psychiatric symptoms).27,28 
 
Two therapeutic strategies are currently utilized in the treatment of CD: 
Strategy # 1: “Step-up” therapy 
Step-up therapy refers to a reactive treatment approach that progressively 
intensifies as disease severity increases. With this approach, a patient with mild to 
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moderate disease would start with a milder, but less toxic first-line agent such as a 5-
ASA. If the 5-ASA fails, treatment would be gradually escalated to a stronger but greater 
risk treatment such as an immunomodulator and/or a biologic.29–31 Such a conventional 
strategy would potentially avoid medication overuse as well as unnecessary exposure to 
possible adverse effects.31  
 
Strategy #2: “Top-down” therapy 
Top-down therapy reverses the conventional step-up therapy by beginning with an 
early introduction of intensive therapy such as biologics in moderate to severe CD, 
aiming to reduce complications and improve quality of life.29,30,31 Studies have shown 
that an early introduction of infliximab in top-down therapy had a longer remission 
period compared to step-up therapy in pediatric patients with moderate to severe CD.32,33  
 
Health Literacy 
Health literacy, according to the Centers for Disease Control and Prevention 
(CDC), refers to “the degree to which a patient can obtain, communicate, process, and 
understand basic health information and services in order to make appropriate 
decisions”.34,35 Improving health literacy is increasingly critical as the complexity of 
health-related choices, tasks and decisions rises with the explosion of publically-available 
health information and technology.36 Results from a pooled analysis of published results 
on health literacy revealed a 26% (95%CI: 22%-29%) weighted prevalence of limited 
health literacy among 31,129 subjects from 85 studies between 1963 and 2004.37 In an 
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early study conducted at two public hospitals in 1995, researchers found that 35.1% of 
English-speaking patients and 61.7% of Spanish-speaking patients had inadequate or 
marginal functional health literacy.38 While improving health literacy is necessary, health 
providers tend to underestimate extent of the problem; this contributes to the challenges 
patients with limited health literacy experience in trying to understand and utilize health 
information.39 
 
Limitations in health literacy are especially great among older patients, 
race/ethnic minorities and undereducated populations.36,40–43 Data from the 2003 National 
Assessment of Adult Literacy (NAAL) found that adults aged ≥ 65 years old had the 
smallest proportion of persons with proficient health literacy skills and the highest 
proportion of persons with health literacy skills below the basic level.36,43 This NAAL 
report also found that Caucasian and Asian/Pacific Islander adults had highest average 
health literacy whereas Hispanic adults had the lowest average health literacy.36,43 In 
addition, the report observed that adults who had not attended or completed high school 
had a higher percentage of Below Basic health literacy than other educational groups.36,43 
The observations from the NAAL report were consistent with the results from several 
other studies, demonstrating that health literacy has been associated with age, 
race/ethnicity, and education.41,42 
 
Health Literacy in Chronic Diseases 
While there are few studies of health literacy in CD, limited health literacy has 
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been associated with a range of poor health-related outcomes in many other chronic 
diseases.44 In a study of indviduals with chronic obstructive pulmonary disease (COPD), 
researchers found associations between limited health literacy and greater disease 
severity, worse quality of life, more emergency utilizations.45,46 Another study in 
asthmatics revealed a strong correlation between limited health literacy and poor 
knowledge of their disease as well as improper use of metered-dose inhaler (MDI), a self-
administered device delivering aerosolized asthma medications into the lungs.47 An 
association between limited health literacy and all-cause mortality and cardiovascular 
death was also found in a prospective cohort study of community-dwelling older adults.48 
Limited HL is significantly related to worse glycemic control and poorer disease 
knowledge in type 2 DM.49 Other studies have found similar associations in hypertension, 
diabetes, and HIV/AIDS.50–52 However, our understanding of the role of health literacy in 
Crohn’s disease is largely based on extrapolation from other chronic diseases.  
 
Health literacy in Medication Use  
Patients with limited health literacy are more likely to have problems 
understanding, managing and adhering to medication instructions.53 In Crohn’s disease, 
patient preference is an important factor when initiating a new treatment such as a 
biologic; most patients want to be involved in this decision.54 Participation in a decision 
pertaining to treatment, a process called “shared-decision making”, demands a certain 
degree of knowledge and health literacy. Although the selection of medications depends 
highly on disease behavior and severity, biologics are recognized as the most effective 
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class of drugs across a range of disease severity, and therefore have the potential to be 
used in moderate, moderate to severe or severe disease). Participation in treatment 
decisions optimizes the chance that the chosen therapy matches the patient’s preference 
and may improve medication adherence.55 Another issue that may be related to health 
literacy in CD populations is self-discontinuation of medication. CD patients who self-
discontinue medications may have done so for a variety of reasons linked to limited 
health literacy such as lack of knowledge or understanding (remission vs. cure, need for 
medication refills, concerns about a side effect), as well as increased barriers to care 
(insurance or financial problems or scheduling conflicts (i.e. – inability to take off work 
for an infusion)). These self-discontinuations often go unreported at the time.  
 
Study Rationale 
The goal of treatment for CD aims to induce and maintain remission. Patients 
must engage in their care throughout the course of treatment in order to achieve these 
goals. There is substantial evidence that patients with limited health literacy have poorer 
health outcomes, as well as difficulties in managing and adhering to medications. 
Because most studies on health literacy were conducted in other chronic disease states, 
knowledge of the role of health literacy in the CD setting is lacking. Understanding how 
health literacy impacts the treatment of CD would help both physicians and patients 
promote physician-patient communication and improve the quality of care delivered. 
Therefore, the aim of the present study was to generate more knowledge on the impact of 
health literacy in CD treatment. More specifically, this study examined whether limited 
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health literacy diminished the effectiveness of treatment, leading to less clinical 
remission, by biasing patient’s preferences on the medication selections and promoting 
the medication self-discontinuations.  
 
Primary Study Objective 
The primary objective was to explore if there was a difference in medication use 
(i.e., medication selection and patient self-discontinuation) between patients with 
adequate and limited health literacy (as measured by Newest Vital Sign scores). 
 
Secondary Study Objectives 
One secondary objective of this study was to examine if there was a difference in 
medication use (i.e., medication selection and patient self-discontinuation) between 
patients who have and who have not achieved clinical remission (as measured by Harvey 
Bradshaw Index score) at the time of recruitment. 
 
Another objective was to investigate if there was effect modification by health 
literacy in the association between medication use (i.e., medication selection and patient 
self-discontinuation) and patient-reported clinical remission (as measured by Harvey 
Bradshaw Index score). 
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METHODS  
Study Design 
This is a secondary analysis of an existing dataset from a cross-sectional IBD 
Health Literacy study conducted within the Gastroenterology department at Boston 
Medical Center. The current study was also a cross-sectional study. Therefore, the 
medications analyzed in this study represented the medications patients were on at the 
time of recruitment in the parent study, and the clinical remission of CD referred to the 
condition whether patients were in remission at the same time. Data were collected 
between Sep. 23, 2014 and Aug. 20, 2015. Both the IBD Health Literacy study and the 
present study were approved by the Institutional Review Board at the Boston University 
School of Medicine. The IBD Health Literacy study measured the associations between 
health literacy and patient-reported outcomes, including subjective health status, and 
quality of life and depression in the setting of IBD populations.  
 
Study population 
Data from ninety-nine subjects from the IBD Health Literacy study were analyzed 
for this study. Of the data set examined, 38 patients were excluded after initial screening 
because they were diagnosed with UC or indeterminate colitis. Accordingly, Sixty-one 
patients were included in this study based on the inclusion/exclusion criteria.  
 
The inclusion criteria included: 
1. Patients who were 18 years old or older. 
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2. Patients diagnosed with CD. 
3. Patients who were proficient in English. 
 
The exclusion criteria included: 
1. Patients who were younger than 18 years old. 
2. Patients who had significant cognitive impairment. 
 
Assessment of Health Literacy 
Health literacy of CD patients was screened by a Newest Vital Sign (NVS) 
questionnaire in the parent study (Appendix 1). The NVS questionnaire, a reliable and 
quick screening instrument with a high sensitivity for limited health literacy in English-
speaking patients, not only evaluates the reading and comprehending abilities, but also 
assesses the quantitative-numerical and abstract reasoning skills.56 The score of NVS 
ranged from 0 to 5; a score of 4-5 was defined as adequate of health literacy, while a 
score of < 3 suggested limited health literacy (Appendix 1). 
 
Assessment of Medication Use 
Data on current and past medication use was collected at the time of clinical 
disease activity assessments (clinical remission vs. active disease). Medication use was 
defined by medication selection and medication self-discontinuation. Medication 
selection was measured by examining the medications that were being taken at the time 
of the recruitment by patients who were on monotherapy from the IBD Health Literacy 
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study. Medication self-discontinuation was defined as whether patients discontinued the 
medication without physician recommendation. This data was collected from medical 
records (provider office visit notes). Based on provider documentation, discontinuation 
was categorized as either patient-directed or provider-directed. Medications reported 
included 5-ASA, immunomodulators (including thiopurines and methotrexate), biologics, 
and prednisone.  
 
Assessment of Clinical Remission 
Data on clinical remission was collected at the time of recruitment in the IBD 
Health Literacy study. Thus, the data represented whether the patients were in remission 
(vs. had active disease) at the time when the data on medication use and health literacy 
levels were collected. Clinical remission of CD was assessed using the patient-reported 
Harvey-Bradshaw Index (HBI) scores (Appendix 2). Based on prior literature, a score <5 
was defined as clinical remission.9,10  
 
Confounders 
            Additional measures, considered to be potential confounders, were obtained in 
this study: age, race/ethnicity, education levels, CD disease behavior and CD disease 
location. These measures were defined: Age was defined as the age at recruitment; 
race/ethnicity was grouped as Caucasians vs. other races; educational levels were 
categorized into higher education level with a college or above education and lower 
education level with a range from illiterate to high school graduate; CD disease behavior 
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and location was measured by the Montreal classification and was collected from medical 
records from the IBD Health Literacy study.  
 
Statistical Analysis 
Demographic characteristics including age, gender, race/ethnicity, disease 
duration, education level, and financial status were assessed using descriptive statistics. 
Baseline measures were compared between the limited health literacy and adequate 
health literacy using the Fisher's exact test for categorical variables and Student's t-test 
for continuous variables. If any of these demographic variables showed a significant 
difference (p < 0.20) between limited and adequate health literacy subgroups, they were 
considered as potential confounders. However, an analysis controlling for potential 
confounders could not be performed due to sample size limitations and lack of available 
information about other key variables including medication dosage and time to initiation 
of medications.  
 
Differences of medication use between limited and adequate health literacy 
subgroups were analyzed using a univariate logistic regression because both variables 
were dichotomized. Detailed descriptions on the seven patients who were taking 
prednisone at the time of recruitment were presented (because all of them were on 
combination therapy). Because HBI score for clinical remission was also dichotomous, a 
univariate logistic regression was performed to analyze the associations of medication 
self-discontinuation with clinical remission. The effect modification analysis of health 
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literacy was conducted by comparing the magnitude of the crude estimator with that of 
stratum-specific estimator in limited and adequate health literacy subgroups.  
 
All statistical analyses were performed in R. A p < 0.05 was considered as 
statistically significant for the results from logistic regressions. 
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RESULTS 
Baseline Characteristics 
From the dataset of the previous IBD Health Literacy study, 99 patients were 
enrolled for initial screening of the present study based on the inclusion/exclusion 
criteria. 38 patients were excluded because they were diagnosed with either UC or 
indeterminate colitis. Within the 61 patients who were enrolled in this study, 26 (43%) 
had limited health literacy (NVS ≤ 3) and 35 (57%) had adequate health literacy 
(NVS>3). The mean age of overall patients was 46.54 yr (SD = 17.66). 40 (66%) patients 
were female, 39 (64%) patients were Caucasian, 40 (66%) patients have an education 
with college or above, and 33 (54%) patients achieved clinical remission at the time of 
visit. The information of the medication monotherapy patients were on at the time of 
recruitment were obtained from medical records: five patients on 5-ASA, three patients 
on thiopurines, three patients on MTX, fourteen patients on biologics. Seven patients who 
were on prednisone at the time of visit were all taking combination therapies. There were 
twenty-five patients on single medication, twenty-six patients on two or three 
medications concurrently, and nine patients not on any medication at the time of 
recruitment. 
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Table 2. Baseline Characteristics 
 
  
 
 
 
 
Baseline Characteristics Limited HL
* (n=26) 
(NVS≤3) 
Adequate HL (n=35) 
(NVS>3) 
Age (mean, SD) 49.6(16.2) 44.3(18.6) 
Age ≥65 yr (%) 4(15%) 8(23%) 
Female (%) 17(65%) 23(66%) 
Caucasian race (%) 10(38%) 29(83%) 
Education with college or above 
(%) 
10(38%) 30(86%) 
CD location** (%)   
L1 (ileal) 4(15%) 12(34%) 
L2 (colonic) 7(21%) 6(17%) 
L3 (ileocolonic) 13(50%) 17(49%) 
CD behavior** (%)   
B2 (stricturing) 5(19%) 9(26%) 
B3 (penetrating) 5(19%) 7(20%) 
P (perianal) 10(38%) 14(40%) 
Medication at visit*** (%)   
5-ASAs* 3(12%) 2(6%) 
Thiopurines 1(4%) 2(6%) 
Methotrexate 1(4%) 2(6%) 
Biologics 4(15%) 10(29%) 
Medication self-DC (%)   
Thiopurines 5(19%) 4(11%) 
Biologics 3(12%) 2(6%) 
Clinical Remission (%)  9(35%) 24(69%) 
* HL = health literacy; medication self-DC = medication self-discontinuation; 5-ASAs= 5-aminosalicylates. 
** CD locations and behaviors are classified by Montreal classification. 
*** Patients who were on monotherapy at the time of visit. 
p < .05 indicated by bold text. 
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Table 2 showed the comparison of baseline characteristics between limited health 
literacy and adequate health literacy. Patients who had limited health literacy were older 
and had a higher percentage of self-discontinuing medications (eg. thiopurines and 
biologics); however, such differences were not statistically significant. The distribution of 
gender in both subgroups was approximately equal. A significantly higher percent of 
patients with adequate health literacy were Caucasian race (p < 0.05) and had received a 
higher education with college or above (p < 0.05). No significant differences in CD 
location and disease behavior were found between limited and adequate health literacy 
subgroups. 
 
Differences of Medication Use in Health Literacy  
A significant association between health literacy and clinical remission was found 
in the previous IBD Health Literacy study. The results for the difference of medication 
selection between limited and adequate health literacy were shown in Table 3. Patients 
who were on biologics at the time of visit were considered reference group in this 
analysis. The odds ratios for 5-ASAs and inmmunomodulators comparing to biologics 
were 3.75 (95%CI (0.46-38.26), p = 0.22) and 1.25 (95%CI (0.13-9.67), p = 0.83). These 
ORs suggested that patients who were on 5-ASAs were almost four times more likely to 
have limited health literacy than patients who were on biologics at the time of visit, and 
the likelihood of those who were on immunomodulators at the time of visit were slightly 
higher than those who were on biologics. Although these differences were clinically 
meaningful to some extent, none of them was statistically significant. 
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 Differences of medication self-discontinuation in different health literacy levels 
were shown in Table 4. The odds ratios showed some clinically meaningful trends, but 
there was no statistically significant difference of medication self-discontinuation 
between limited and adequate health literacy. The odds ratio for patients who self-
discontinued thiopurines versus those who did not self-discontinue the same medication 
was 1.98 (95%CI (0.44-9.46), p = 0.37); the odds ratio for those who self-discontinued 
biologics against those who did not was 2.67 (95%CI (0.38-23.30), p = 0.33). This 
suggested that patients with limited health literacy were more likely to discontinue these 
two medications without physician recommendations than those with adequate health 
literacy who were on the same medication. The results of patients who self-discontinued 
any medications versus those who did not were also presented; the odds ratio was 1.62 
(95%CI (0.42-6.24), p = 0.48). Although the trend remains the same, the odds ratio was 
lower than thiopurines and biologics groups in separate. This indicated that there might 
be some other factors interfering the associations.  
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Table 3. Unadjusted analysis on differences of medication selection at the time of visit 
in health literacy. 
 Limited Health Literacy 
 OR 95%CI P-value 
(Intercept)* (n=14) - - - 
5-ASAs (n=5) 3.75 0.46-38.26 0.22 
Immunomodulators** (n=6) 1.25 0.13-9.67 0.83 
*     Intercept represents patients who were on biologics monotherapy at the time of recruitment in IBD 
Health Literacy study. 
**    Inmmunomodulators include methotrexate and thiopurines. 
 
 
Table 4. Unadjusted analysis on differences of medication self-discontinuation in health 
literacy. 
 Limited Health Literacy 
 OR 95%CI P-value 
Thiopurine    
(Intercept)* (n=31) - - - 
Self-DC** (n=9) 1.98 0.44-9.46 0.37 
Biologics    
(Intercept)* (n=25) - - - 
Self-DC (n=5) 2.67 0.38-23.30 0.33 
Total medications***    
(Intercept)* (n=34) - - - 
Self-DC (n=12) 1.62 0.42-6.24 0.48 
*    Intercept represents patients who did not discontinue the same medication without physician 
recommendation. 
**   Paitents who discontinued the medication without physician recommendation.  
***  Patients whoever self-discontinued any medications vs. those who did not; the numbers of patients do 
not add up because there were patients who were on both medications. 
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Medication Self-discontinuation and Clinical Remission of CD 
Table 5 showed the results for the differences of medication self-discontinuation 
in clinical remission of CD. There were no statistically significant differences in clinical 
remission of CD, even though the trends had some clinical meaning. Patients who self-
discontinued thiopurines and biologics were less likely to be in clinical remission of CD 
than those who did not self-discontinue the same medication; the odds ratios were 0.55 
(95%CI (0.11-2.81), p = 0.47) and 0.15 (95%CI (0.01-1.21), p = 0.11), respectively. The 
results of patients whoself-discontinued any medication versus those who did not showed 
that patients whoever had discontinued their medication without physician 
recommendation were less likely to be in clinical remission of CD, and the odds ratio for 
this association was 0.46 (95%CI (0.1-1.85), p = 0.27).  
 
Health Literacy Associated Differences in the Associations Between Medication Use 
and Clinical Remission (Effect Modification by Health Literacy) 
 Although the associations between medication selection and clinical remission 
were analyzed by this study (Appendix 3), this study failed to detect health literacy 
associated differences in this association due to the small sample size. There was no 
effect modification by health literacy in association between thiopurine self-
discontinuation and clinical remission of CD, meaning that there were no health literacy 
associated differences in this association (Table 6). The odds ratios for the associations 
between thiopurines self-discontinuation and clinical remission were 1.0 (95%CI (0.10-
9.12), p = 1.0) in the limited health literacy subgroup and 0.57 (95%CI (0.04-14.16), p = 
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0.68) in the adequate health literacy subgroup. This might suggest that patients with 
adequate health literacy who self-discontinued thiopurines were less likely to be in 
clinical remission (compared to patients with limited health literacy who self-
discontinued the same medication), but the results in both health literacy subgroups were 
not statistically significant and the statistical power for this difference was small. Table 7 
showed the results on health literacy associated difference in the association between 
biologics self-discontinuation and clinical remission. However, this difference was 
undetectable because there were no patients with limited health literacy who were in 
clinical remission and had a history of biologics self-discontinuation simultaneously.  
 
Health literacy associated difference in the associations between total medication 
self-discontinuation and clinical remission were showed in Table 8. Although odds ratios 
for both health literacy subgroups (OR = 0.6, 95% CI (0.06-4.58) for limited health 
literacy and OR = 0.5, 95%CI (0.06-4.62) for adequate health literacy) showed that 
patients with both limited and adequate health literacy who had self-discontinued any 
medication were less likely to be in clinical remission, the difference (of the association 
between medication self-discontinuation and clinical remission of CD) between limited 
and adequate health literacy groups was not significant.  
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Table 5. Unadjusted associations between medication self-discontinuation and clinical 
remission of CD. 
 Clinical Remission of CD (HBI<5) 
 OR 95%CI P-value 
Thiopurines    
(Intercept)* (n=31) - - - 
Self-DC** (n=9) 0.55 0.11-2.81 0.47 
Biologics    
(Intercept)* (n=25) - - - 
Self-DC (n=5) 0.15 0.01-1.21 0.11 
Total medications***    
(Intercept)* (n=34) - - - 
Self-DC (n=12) 0.46 0.11-1.85 0.27 
*    Intercept represents patients who did not discontinue the same medication without physician 
recommendation. 
**   Paitents who discontinued the medication without physician recommendation.  
***  Patients whoever self-discontinued any medications vs. those who did not; the numbers of patients do 
not add up because there were patients who were on both medications. 
 
 
Table 6. Health literacy associated differences in the association between thiopurines 
self-discontinuation and clinical remission. 
 No self-DC* Thiopurines self-DC  
 N with/without 
clinical remission 
N with/without 
clinical remission 
OR (95%CI) for 
thiopurines self-DC within 
each stratum of HL 
Limited HL** 4/6 2/3 1.0 (0.10-9.12), p = 1.0 
Adequate HL 14/4 2/1 0.57 (0.04-14.16), p = 0.68 
*  Self-DC refers to patients who discontinued the medication without physician recommendation. 
** HL = Health Literacy. 
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Table 7. Health literacy associated differences in the association between biologics self-
discontinuation and clinical remission. 
 No self-DC* Biologics self-DC  
 N with/without 
clinical remission 
N with/without 
clinical remission 
OR (95%CI) for biologics 
self-DC within each 
stratum of HL 
Limited HL** 4/4 0/3 NA 
Adequate HL 11/5 1/1 0.45 (0.02-13.08), p = 0.60 
*  Self-DC refers to patients who discontinued the medication without physician recommendation. 
** HL = Health Literacy. 
 
 
Table 8. Health literacy associated differences in the association between total medication 
self-discontinuation and clinical remission. 
 No self-DC Medication self-DC*  
 N with/without 
clinical 
remission 
N with/without 
clinical remission 
OR (95%CI) for total 
medication self-DC within 
each stratum of HL 
Limited HL** 5/6 2/4 0.6 (0.06-4.58), p = 0.63 
Adequate HL 15/5 3/2 0.5 (0.06-4.62), p = 0.51 
*  This analyzed patients whoever discontinued any medication without physician recommendation vs. 
those who did not; self-DC = self-discontinuation. 
** HL = Health Literacy. 
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Table 9. Details on the 7 patients who were taking prednisone at the time of visit. 
ID 1 2 3 4 5 6 7 
Agea 48 33 47 63 67 36 46 
Sex F F F F M F M 
Caucasian Y N Y Y Y N Y 
Educationb N N Y N N N N 
HLc A L A L A L A 
HBId - R - - - R - 
5-ASAe - - - Y - - - 
Thiopurines - Y - - - Y - 
MTXf Y - - - Y - - 
Biologics Y - Y Y - Y Y 
a   Age at the visit 
b   Education with college or above (Y: Yes, N: No) 
c   HL = Health Literacy (A = Adequate, L = Limited) 
d   Assessment of clinical remission of CD (R: Remission(HBI<5)) 
e   5-ASAs = 5-Aminosalicylates (Y: Yes) 
f     MTX = Methotrexate 
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DISCUSSION 
This study first explored the difference in medication use (defined by medication 
selection and medication self-discontinuation) between CD patients with limited and 
adequate health literacy. Next, the difference in medication use between patients with and 
without clinical remission was investigated. Finally, health literacy associated differences 
in the associations between medication self-discontinuation and clinical remission of CD 
were examined. 
 
Unadjusted analysis revealed that there was no statistically significant difference 
in medication selection between patients with limited and adequate health literacy who 
received monotherapy of 5-ASAs, biologics, and immunomodulators. Medication self-
discontinuation rate was not significantly different across the health literacy spectrum. 
Moreover, prior medication self-discontinuation appeared to have no difference in current 
clinical disease activity (remission vs. active disease). Lastly, there was no health literacy 
associated differences in the association between medication self-discontinuation and 
clinical remission of CD. 
 
Study Population 
This study was conducted by analyzing an existing dataset from the IBD Health 
Literacy study within the GI department at Boston Medical Center. The distribution of 
age at diagnosis in this study population revealed a peak between 20 and 30 years old and 
a median age of 28 years old. Also, approximately 65% patients in this study were 
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female. These findings were similar to prior studies: a retrospective study in the United 
Kingdom found that 62% were female and the median age of diagnosis was 30 years 
old57,58; a retrospective study in Olmsted County, Minnesota, United States showed that 
54% of the study population were female and the median age of diagnosis was 29.5 years 
old58,59; another prospective study found a female predominance and a median of age at 
diagnosis of 31 years old.58,60 In addition, there was predominance in Caucasian race 
(64%) and a smaller percentage in African American (20%) in this study, which was 
roughly similar to the prevalence of general CD population. Therefore, the results of this 
study suggest generalizability to the CD population at large but with caution due to other 
potential differences such as socioeconomic status and cultural differences. 
 
Differences of Medication Use in Patients’ Health Literacy Levels 
The treatment for CD is a shared decision making process that requires patients to 
make preference-sensitive decisions in order to optimize the treatment response and 
improve adherence to treatment.55,61 Health literacy is crucial to this process in that low 
health literacy limits the patients’ ability to communicate with health care providers, 
understand disease-associated knowledge, and participate in the shared-decision making 
process.62 However, the magnitude of the influence by patients’ limited health literacy in 
this process remains unknown. The absence of a significant difference of medication 
selection between patients with limited and adequate health literacy suggests that the 
effective medications were equally used across the health literacy spectrum in this 
population.  
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While patients’ desire to be actively involved in the preference-sensitive decision-
making process, Siegel et al discovered that gastroenterologists lack the approach and 
tools to implement the shared-decision making process.63 This could be another reason 
for the lack of observable difference in medication selection across health literacy levels. 
In some instances, gastroenterologists may take a more paternalistic approach, thereby 
diminishing the impact of the patient’s health literacy on a treatment selection. 
(Something like – “In contrast to those with adequate health literacy, patients with limited 
health literacy often feel less empowered and are more likely to report dissatisfaction 
with patient-provider communication and shared-decision making (I think you can find a 
study from my paper that reported something like this). They may be more likely to 
experience a paternalistic approach, which often fails to adequately engage the patient 
and ascertain patient preferences as part of the decision making process). A lack of 
engagement in the treatment decision may increase patients’ vulnerability to the potential 
harms of treatment through multiple potential mechanisms: lack of understanding of 
treatment benefits, risks, alternatives and expectations as well as inadequate strategies for 
self-management and involving the provider, when confronting troubles. Therefore, as it 
appears effective medications are likely to be equally used in limited and adequate health 
literacy subgroups, health care providers need to be cognizant of health literacy 
challenges and work to create a supportive and engaging environment for vulnerable 
patients 
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            If we accept a premise that medication self-discontinuation can be either 
intentional (i.e., deliberate discontinuation due to dissatisfaction with the medication) or 
unintentional (i.e., lack of knowledge or awareness about the need to “refill” a 
medication), then this concept has similarities to intentional and unintentional non-
adherence. This is a complex concept as it relates to health literacy. When looking 
broadly at adherence, studies have failed to find a consistent link with health literacy: 
Dharmapuri et al reported that almost one quarter of adolescents had worse medication 
adherence, independent of health literacy.64 Lyles et al also failed to find an association 
between health literacy and medication adherence.65 Similar to the present study, these 
studies did not distinguish between intentional and unintentional non-adherence either.  
 
Other studies have shown that patients with limited health literacy are more prone 
to unintentional non-adherence, but not necessarily intentional non-adherence.66,67 
Frequently less empowered to make health decisions, patients with limited health literacy 
may be less likely to intentionally self-discontinue their medications without direction 
from their doctor, but they may still be more prone to unintentional self-discontinuation. 
Findings from the present study failed to show differences of self-discontinuation of 
thiopurines and biologics between CD patients with limited and adequate health literacy, 
possibly because the distinction between intentional and unintentional behaviors could 
not be made. 
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 That said, it is worthwhile to note that there are a few studies that have found 
significant association between health literacy and medication adherence overall. Waite 
et al found that HIV patients with limited health literacy were 3.3 times more likely to be 
non-adherent to antiretroviral regimens.68 Noureldin et al also found that patients with 
limited health literacy had lower adherence to cardiovascular drugs than those with 
adequate health literacy.69 Despite the small sample size of the present study, the odds 
ratios for medication self-discontinuation according to health literacy still reflect a trend 
that patients with limited health literacy were more likely to discontinue their medications 
without physician recommendation. One major difference between the studies that had 
statistically significant results and the present study was the sample size: Waite et al 
recruited 204 patients and Noureldin et al had 314 patients. The trend, which is consistent 
with the trends in the two aforementioned studies, suggests that there is a possibility that 
the difference in medication self-discontinuation between limited and adequate health 
literacy can be detected with a larger sample size. 
 
            Contrary to the trends detected in the present study, one study by Michael et al 
found a reverse trend: low health literacy was associated with higher odds of medication 
adherence in HIV populations in a longitudinal study.70 While this may also be the 
situation in CD populations, such that patients who self-discontinue thiopurines and 
biologics do so because they think they have better understanding of when to stop their 
medications, the present study is not able to distinguish the actual motivation, whether it 
is due to limited health literacy or adequate health literacy. However, the HIV population 
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is different from CD population in many aspects such as age, sex and race. For example, 
there are more male patients than females in HIV population,71 but in this study females 
are the predominant sex. Some studies have shown that women are more vulnerable to 
nonadherence and men are more adherent to medications.72–74 Therefore, relationship 
between low health literacy and adherence may be unique for male-dominant HIV 
populations but not suitable for CD populations. The trends found in the present study, on 
the contrary, may provide a foundation for health literacy associated differences in 
medication use specifically for CD populations. 
 
Associations Between Medication Self-discontinuation and Clinical Remission of CD 
At first glance, the lack of significant differences between medication self-
discontinuation behavior and the clinical remission of CD in the current study suggests a 
potential departure from prior studies. In a case-control study examining the role of 
medication adherence in IBD, Feagins et al found that medication adherence was 
significantly different in disease activities and that medication non-adherence was 
significantly associated with IBD flares.75 The CD population in the Feagins et al. study 
was similar in size to the present study; however, the difference of medication adherence 
in different disease activities was found amongst the entire IBD population, and therefore 
included patients with UC. It is notable that UC is a much more homogenous disease than 
CD. On the contrary, a longitudinal study conducted by Mantzaris et al in a solely CD 
population with a smaller sample size of 30 patients did not find a significant relationship 
between  medication adherence and clinical remission.76 Studies examining medication 
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adherence and clinical remission in CD populations may be limited in their ability to 
detect a difference in part due to disease heterogeneity. Studies, including the present 
study, may also require larger sample sizes than examined in order to detect these 
differences. 
 
When compared to other studies in CD that examined differences in medication 
use according to clinical disease activity (remission vs. active disease), there are several 
notable differences that likely contribute to the lack of significant findings in this study. 
First, key variables including disease location, disease severity, medication duration and 
dosage were closely associated with the clinical remission of CD and were able to be 
controlled for in the aforementioned studies. For example: Ho et al reported increased 
risk of treatment failure of corticosteroids in patients with fistulizing and stricturing CD 
at diagnosis;77 Summers et al, Malchow et al, and Van Hees et al demonstrated 5-ASA at 
dosage between 3-6g/day to be a benefit over placebo in inducing remission in patients 
with mild to moderate CD;78–80 Finally, Patel et al provided evidence that low dose 
methotrexate (15mg/week) was superior to placebo for maintenance of remission in 
CD.25 However, specific information about medication dosage and duration of use was 
not uniformly available in this study’s dataset, thus limiting the ability of the present 
study to adjust for these factors. Information regarding disease location and severity was 
available; however, the present study could not account for these factors due to the small 
sample size.  
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Health Literacy Associated Differences in the Associations Between Medication Self-
discontinuation and Clinical Remission of CD  
Despite the lack of significant difference in medication self-discontinuation across 
health literacy levels, there was a significant difference in the clinical remission rate 
across health literacy level in this study sample (found in the IBD Health Literacy study). 
Therefore, it is reasonable to look at whether health literacy would impact the 
relationship between medication self-discontinuation and clinical remission. The results 
showed that there was no effect modification by health literacy in the associations 
between medication self-discontinuation and clinical remission of CD, meaning that there 
was no significant health literacy associated difference in these associations. The odds 
ratio was undetectable in patients who self-discontinued biologics and had limited health 
literacy because there were no patients in this subgroup in clinical remission. The odds 
ratios of thiopurine self-discontinuation in clinical remission were 1.0 (95%CI (0.10-
9.12)) in limited health literacy and0.57 (95%CI (0.04-14.16)) in adequate health literacy; 
however, the “crude estimator” (OR=0.55, 95%CI (0.11-2.81)) was not in between the 
stratum-specific odds ratios. In addition, the “crude estimator” (OR = 0.46, 95%CI (0.11-
1.85), p = 0.27) of total medication self-discontinuation was not in between the stratum-
specific odds ratios for adequate (OR = 0.5, 95%CI (0.06-4.62), p = 0.51) and limited 
health literacy subgroups (OR = 0.6, 95%CI (0.06-4.58), p = 0.63).    
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The observed trend in the association between medication self-discontinuation 
and clinical remission of CD did not vary according to health literacy level. The lack of 
significant health literacy-based differences may be due to the ambiguity of the term 
“self-discontinuation”, the small sample size of the present study or a true null result. In 
the case of the latter, it suggests that patients with both limited and adequate health 
literacy require support from health care providers throughout the treatment course. 
Health care providers not only need to consider patient preferences when prescribing 
medication, but also need to educate and engage patients in open communication about 
medication concerns, irrespective of health literacy. However, we hypothesize that the 
nature of the concerns, the support needed and the form in which this takes may vary 
according to health literacy, and further studies could seek to explore this.  
 
Limitations 
            Several limitations related to sample size, assessments, confounders and analytic 
methods could affect the validity of the results. The small sample size limited statistical 
power, and thus reduced the chance of detecting a true effect. The small sample size of 
this study also limited the ability to control for various potential confounders. This might 
be the reason that the results have shown some trends that were reasonable in clinical 
care but not statistically significant. A sample size calculation and a power test were thus 
recommended in future analysis before initiating the study.  
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            Another limitation would be the failure to control for factors that could potentially 
affect the associations investigated in this study. Race and education level are associated 
with health literacy. Caucasians and people who received a college education or above 
were found to have higher health literacy. Disease location, disease severity and disease-
associated complications are critical when making treatment decisions.2 Dosage of 
medications was also important and many prior studies have analyzed a medication dose-
related association with CD remission..25,81 Route of administration can also affect 
patient’s adherence to medications and the benefits of therapy.82 Time to initiation of 
immunomodulators could affect the efficacy of treatment for CD. Corticosteroids usually 
take 1-2 week to show benefits; therapeutic onset of thiopurines is about 12-17 weeks 
from initiation.11,14,15 The failure to control for these factors in the present study was due 
to multiple reasons. Some factors such as race, education level, disease location, disease 
severity and disease-associated complications, were collected but not analyzed because of 
small sample size; others were unavailable from the original dataset. The associations 
investigated in this study could either be strengthened or diminished if these factors are 
controlled. 
 
            Although the assessment of self-discontinuation can partially reflect medication 
adherence, it is still limited in the ability to accurately represent the actual conditions.  
Patients who may not have self-discontinued the medication, but could have been  
modifying  the frequency of  their use because of intolerance (i.e. - adverse effects) or 
self-titrating the dose  to achieve a desired effect . These patients would not have been 
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captured as “self-discontinuing” their medication, but also would not meet the standard 
definition of “adherent”. The low specificity of self-discontinuation could reduce the 
observable difference in clinical remission between patients who self-discontinued the 
medication and who did not. There are many validated assessments of medication 
adherence in previous studies and one of them is Medication Possession Ratio (MPR). 
MPR is the sum of the days’ supply for all fills of a given drug in a certain period of time, 
divided by the numbers of days in this period.83 If a patient missed a few refills during 
this period, then the MPR would be low; MPR would also be low if a patient self-
discontinued the medication. Therefore, MPR has a wider coverage of medication 
adherence. 
 
            This study also failed to differentiate whether the patient was in an induction 
period or a maintenance period of remission. This is important because medications such 
as thiopurines and biologics can be used in both processes while other medications were 
more effective in one process than the other. Medication and clinical remission data were 
collected at one time point rather than longitudinally; itt would be difficult for a cross 
sectional study to determine whether the patient is newly induced into remission or has 
been in the remission for a longer period of time. A longitudinal dataset would better 
describe such difference. 
 
            As the data of self-discontinuation was obtained from medical records by 
researchers in the Health Literacy IBD study, there was a risk of researcher bias in this 
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process. Even though the criteria for determining provider-directed discontinuation 
versus patient-directed discontinuation were predefined, the researchers might find it hard 
to determine the boundary between the two. There is a chance that the medical records 
showed that the patients stopped the medication because of patient-reported side effects, 
and one researcher consider it as a self-discontinuation while another researcher consider 
it as a suspension by the provider. If the number of these types of discrepancies  is large 
enough, then there could be either an increase or a decrease in the effect of self-
discontinuation on the clinical remission of CD. 
 
Future Directions 
            Future studies are necessary to explore how health literacy affects the treatment 
and health outcomes in CD populations in order to support the results of present study. A 
larger sample size is a must in order to increase the power of detecting the differences of 
health literacy on medications and clinical remission of CD. Studies of the same design 
with a larger sample size need to adjust for several factors, including race, education, 
disease location, disease severity, disease-associated complications. A prospective cohort 
study on the differences of medication adherence between patients with limited and 
adequate health literacy specifically in CD is an option; a prospective or retrospective 
cohort study on the relationships of health literacy to self-discontinuation behaviors 
(intentional or nonintentional) in CD patients can be another choice. These studies would 
potentially help better understand the impact of variable health literacy on the treatment 
CD, and also improve the health care system to provide sufficient support for self-
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management of medications. (i.e. – “Future studies involving patients at all levels of 
health literacy should consider using mixed methods to explore health system elements 
needed to address aspects of medication management support and shared decision 
making in order to achieve health equity.”) 
 
Conclusions 
            This cross-sectional study investigated differences in medication use between CD 
patients with limited and adequate health literacy, differences in medication self-
discontinuation between patients with and without clinical remission of CD, and health 
literacy associated differences in the association between medication self-discontinuation 
and clinical remission of CD. No significant health literacy associated differences were 
found in medication use, or between medication self-discontinuation and clinical 
remission of CD. Lack of differences in medication use between patients with limited and 
adequate health literacy suggests that effective medications are likely being used equally 
amongst limited and adequate health literacy subgroups in this population. The lack of a 
health literacy effect on the observable trend in the association between medication self-
discontinuation and clinical remission of CD  suggests that open communication and self-
management support is needed for patients across all health literacy levels,  though the 
most effective form of support may vary and needs further exploration Despite 
limitations, the findings of this study offer valuable knowledge regarding health literacy 
associated differences in medication selection, medication self-discontinuation, and 
clinical disease activity in CD. This knowledge could be used to support future work to 
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optimize the efficacy of treatment for CD by improving  health care system delivery 
support for patients  across health literacy levels. 
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APPENDIX 1 
 
 
 
 
 
 
Dear Healthcare Professional: 
 
Thank you for your interest in the Newest Vital Sign (NVS), the first tool available to assess health 
literacy in English and Spanish. 
 
Research shows that patients with low health literacy are less likely to comply with prescribed treatment 
and medical instructions from their physician. Identifying patients who are at risk for low health literacy 
allows physicians to apply specific clear health communication techniques that may enhance 
understanding. The Newest Vital Sign is a simple and fast way to identify those patients. The tool, which 
tests literacy skills for both numbers and words*, has been validated against a previously validated 
measure of health literacy (the TOFHLA), and has been shown to take approximately three minutes to 
administer. 
 
In addition to the NVS tool, we are also including information to help enhance patient-provider 
communication. In this folder you will find the following materials: 
 
 NVS Tool (nutrition label and scoring sheet tear-off pad, both two-sided in English/Spanish) 
 NVS Implemenation Guide 
 Ask Me 3 (fact sheet on free educational materials from the non-profit Partnership for Clear 
Health Communication) 
 Help Your Patients Succeed (tips for improving communication with your patients) 
 Why Does An Ice Cream Label Work . . . (fact sheet explaining the design of the NVS) 
 
The Newest Vital Sign is Pfizer Inc’s most recent contribution to the health literacy movement. For more 
than nine years, Pfizer has been committed to raising awareness of developing solutions for low health 
literacy. The overall goal of our Clear Health Communication Initiative is to positively impact the health 
care system by enhancing patient-provider communication to increase compliance and improve patient 
health outcomes.  
 
The Newest Vital Sign and companion materials are available to medical and public health providers at 
no cost. To learn more about our efforts to improve health literacy, please visit 
www.pfizerhealthliteracy.com. 
 
Sincerely,  
 
Richard C. Hubbard, M.D. 
Senior Director, External Medical Affairs 
Pfizer Inc 
 
*Literacy is defined as the understanding and application of words (prose), numbers (numeracy), and 
forms, etc. (document).  
February 2011 
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Implementation Guide for the Newest Vital Sign 
 
Health literacy— the ability to read, understand and act upon health information — is now 
known to be vital to good patient care and positive health outcomes. According to the Institute 
of Medicine’s groundbreaking report on health literacy, nearly half of all American adults — 90 
million people — have difficulty understanding and using health information. When patients 
lack the ability to understand and act upon medical information, it can put their health at risk. 
 
The Newest Vital Sign is a new tool designed to quickly and simply assess a patient’s health 
literacy skills. It can be administered in only 3 minutes and is available in English and Spanish. 
The patient is given a specially designed ice cream nutrition label to review and is asked a series 
of questions about it. Based on the number of correct answers, health care providers can assess 
the patient’s health literacy level and adjust the way they communicate to ensure patient 
understanding. 
 
There are many ways to integrate the Newest Vital Sign (NVS) into a private practice or clinic 
setting to improve communication with patients. Improved communication can help increase 
your patients’ ability to understand and act upon the information you provide; ultimately 
improving patient satisfaction and health outcomes.  
 
How To Use the Newest Vital Sign 
 
1. Who and when to administer the Newest Vital Sign. 
 A nurse (or other trained clinic staff) is the preferred administrator of the Newest 
Vital Sign. 
 Administer at the same time that other vital signs are being taken.  
2. Ask the patient to participate. 
A useful way to ask the patient is an explanation similar to this: 
“We are asking our patients to help us learn how well patients can understand the 
medical information that doctors give them. Would you be willing to help us by 
looking at some health information and then answering a few questions about that 
information? Your answers will help our doctors learn how to provide medical 
information in ways that patients will understand. It will only take about 3 minutes.” 
3. Hand the nutrition label to the patient. 
The patient can and should retain the nutrition label throughout administration of the 
Newest Vital Sign. The patient can refer to the label as often as desired. 
More… 
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4. Start Asking the 6 questions, one by one, giving the patient as much time as needed to 
refer to the nutrition label to answer the questions. 
 There is no maximum time allowed to answer the questions. The average time 
needed to complete all 6 questions is about 3 minutes. However, if a patient is still 
struggling with the first or second question after 2 or 3 minutes, the likelihood is 
that the patient has limited literacy and you can stop the assessment.  
 Ask the questions in sequence. Continue even if the patient gets the first few 
questions wrong. However, if question 5 is answered incorrectly, do not ask 
question 6. 
 You can stop asking questions if a patient gets the first four correct. With four 
correct responses, the patient almost certainly has adequate literacy. 
 Do not prompt patients who are unable to answer a question. Prompting may 
jeopardize the accuracy of the test. Just say, “Well, then let’s go on to the next 
question.” 
 Do not show the score sheet to patients. If they ask to see it, tell them that “I can’t 
show it to you because it contains the answers, and showing you the answers spoils 
the whole point of asking you the questions.” 
 Do not tell patients if they have answered correctly or incorrectly. If patients ask, 
say something like: “I can’t show you the answers till you are finished, but for now 
you are doing fine. Now let’s go on to the next question.” 
5. Score by giving 1 point for each correct answer (maximum 6 points). 
 Score of 0-1 suggests high likelihood (50% or more) of limited literacy. 
 Score of 2-3 indicates the possibility of limited literacy. 
 Score of 4-6 almost always indicates adequate literacy. 
Record the NVS score in the patient’s medical record, preferably near other vital sign 
measures. 
 
 
Best Practices for Implementation: Summary 
 A nurse (or other trained clinic staff) is the preferred administrator of the Newest 
Vital Sign. 
 Administer the NVS at the same time that the patient’s other vital signs are being 
taken. 
 Record the NVS score in the patient’s chart, preferably near other vital sign 
measures. 
 Tailor communication to ensure patient understanding. 
www.pfizerhealthliteracy.com 
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Why Does an Ice Cream Label Work as a Predictor  
of the Ability To Understand Medical Instructions? 
 
A patient’s ability to read and analyze any kind of nutrition label requires the same analytical and 
conceptual skills that are needed to understand and follow a provider’s medical instructions. The skills, 
which are known as health literacy, are defined as the understanding and application of words (prose), 
numbers (numeracy), and forms (documents). 
 
The use of an ice cream label is especially relevant as recent research in the American Journal of 
Preventive Medicine (November 2006) has shown that poor comprehension of food labels correlated 
highly with low-level literacy and numeracy skills. However, the study found that even patients with 
better reading skills could have difficulties interpreting the labels. 
 
Whether reading a food label or following medical instructions, patients need to: 
 
 remember numbers and make mathematical calculations. 
 identify and be mindful of different ingredients that could be potentially harmful to them. 
 make decisions about their actions based on the given information. 
 
PROSE LITERACY: 
Clinical example: The patient has scheduled some blood tests and is instructed in writing to fast the 
night before the tests. The skill needed to follow this instruction is Prose Literacy. 
 
Ice cream label example: The patient needs this skill to read the label and determine if he can eat the ice 
cream if he is allergic to peanuts. 
 
NUMERACY: 
Clinical example: A patient is given a prescription for a new medication that needs to be taken at a 
certain dosage twice a day. The skill needed to take the medication properly is Numeracy. 
 
Ice cream label example: The patient needs this same skill to calculate how many calories are in a 
serving of ice cream. 
 
DOCUMENT LITERACY:  
Clinical example: The patient is told to buy a glucose meter and use it 30 minutes before each meal and 
before going to bed. If the number is higher than 200, he should call the office. The skill needed to 
follow this instruction is Document Literacy. 
 
Ice cream label example: The patient needs this skill to identify the amount of saturated fat in a serving 
of ice cream and how it will affect his daily diet if he doesn’t eat it. 
 
www.pfizerhealthliteracy.com February 2011 
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Score Sheet for the Newest Vital Sign 
Questions and Answers 
READ TO SUBJECT:  
This information is on the back of a container of a pint of ice cream. 
1. If you eat the entire container, how many calories will you eat?
Answer: 1,000 is the only correct answer
2. If you are allowed to eat 60 grams of carbohydrates as a snack, how much ice
cream could you have?
Answer: Any of the following is correct: 1 cup (or any amount up to 1 cup),
half the container. Note: If patient answers “two servings,” ask “How much ice
cream would that be if you were to measure it into a bowl?”
3. Your doctor advises you to reduce the amount of saturated fat in your diet.
You usually have 42 g of saturated fat each day, which includes one serving of
ice cream. If you stop eating ice cream, how many grams of saturated fat would
you be consuming each day?
Answer: 33 is the only correct answer
4. If you usually eat 2,500 calories in a day, what percentage of your daily value
of calories will you be eating if you eat one serving?
Answer: 10% is the only correct answer
READ TO SUBJECT:  
Pretend that you are allergic to the following substances: penicillin, peanuts, 
latex gloves, and bee stings. 
5. Is it safe for you to eat this ice cream?
Answer: No
6. (Ask only if the patient responds “no” to question 5): Why not?
Answer: Because it has peanut oil.
Number of correct answers: 
ANSWER CORRECT? 
yes no 
Interpretation 
Score of 0-1 suggests high likelihood (50% or more) of limited literacy. 
Score of 2-3 indicates the possibility of limited literacy. 
Score of 4-6 almost always indicates adequate literacy.  
February 2011 
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APPENDIX 2 
 
 
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9 
© 2011 JANSSEN Inc.
www.janssen.ca
RGFM110565E
*All trademark rights used under license
Please check one box per number (except for #5)
References: 1. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514. 2. British Columbia Ministry of Health Services. Worksheet based on the Harvey-Bradshaw 
Index. British Columbia Ministry of Health Services website. https://www.health.gov.bc.ca/exforms/pharmacare/5374fil.pdf. Accessed September 23, 2010.  
1.  General well-being 
(yesterday)
 Very well = 0
 Slightly below par = 1
 Poor = 2
 Very poor = 3
 Terrible = 4
2.  Abdominal pain 
(yesterday)
 None = 0
 Mild = 1
 Moderate = 2
 Severe = 3 
3.  Number of liquid or soft stools per day (yesterday) =  ___________________  
4. Abdominal mass  None = 0
 Dubious = 1
 Definite = 2
 Definite and tender = 3
5.  Complications 
(check any that apply; score one 
per item except for first box)
 None
 Arthralgia
 Uveitis
 Erythema nodosum
 Aphthous ulcers
 Pyoderma gangrenosum
 Anal fissure
 New fistula
 Abscess
Harvey-Bradshaw Index score2= 
Remission <5
Mild disease  5-7
Moderate disease  8-16
Severe disease  >16
(please add scores of questions  
1 through 5)
For formulary coverage: 
Harvey-Bradshaw Index (HBI) — 
A simple index of Crohn’s disease activity1
Patient name:  
Date of HBI calculation:  
 50 
APPENDIX 3 
Unadjusted analysis on differences of medication selection at the time of visit in 
patients’ disease activities (remission vs. active disease). 
 
 Clinical Remission of CD (HBI<5) 
 OR 95%CI P-value 
(Intercept)* (n=14) - - - 
5-ASAs (n=5) 0.30 0.03-2.46 0.27 
Immunomodulator** (n=6) 0.89 0.11-8.37 0.91 
*     Intercept represents patients who were on biologics monotherapy at the time of visit 
**    Inmmunomodulator include methotrexate and thiopurines 
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LIST OF JOURNAL ABBREVIATIONS 
 
 ????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????? 
 
Aliment Pharmacol Ther Alimentary Pharmacology & Therapeutics 
 
Am Heart J A????????????????????? 
 
Am J Gastroenterol   The American Journal of Gastroenterology 
 
Am J Health Behav   American Journal of Health Behavior 
 
Am J Respir Crit Care Med ???????????????????????????????????????????? ????
?????????
  
Ann Fam Med    Annals of Family Medicine  
 
Arch Intern Med   Archives of Internal Medicine 
 
Arthritis Res Ther   Arthritis Research & Therapy 
 
Blood Press Monit   Blood Pressure Monitoring 
 
????????????????????????????????????????????????????????????????????????
?
Clin Gastroenterol Hepatol  Clinical Gastroenterology and Hepatology 
 
Cochrane Database Syst Rev  The Cochrane Database of System???? Reviews 
 
Consult Pharm The Consultant Pharmacist: The Journal of the 
American Society of Consultant Pharmacist? 
 
?????????????????????????????????????????????????????????????????????
?
Curr Opin Gastroenterol  Current Opinion in Gastroenterology 
 
Di???????????                          The Dibetes Educator 
 
Dig Dis    Digestive Disease? (Basel, Switerland) 
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Expert Rev Gastroenterol Hepatol Expert Review of Gastroenterology & Hepatology  
 
Expert Opin Pharmacother  Expert Opinion on Pharmacotherapy 
 
Fam Med    Family Medicine 
 
Inflamm Bowel Dis   Inflammatory Bowel Diseases 
 
JAMA     Journal of the American Medical Association 
 
J Adv Nurs                                          Journal of Advanced Nursing 
 
J Crohns Colitis   Journal of Crohn’s & Colitis 
 
J Gen Intern Med   Journal of General Internal Medicine 
 
J Pediatr    The Journal of Pediatrics 
 
J Pediatr Gastroenterol Nutr  Journal of Pediatric Gastroenterology and Nutrition 
 
Med Arh    Med?cinski Arhiv 
 
NEJM     New England Journal of Medicine 
 
Natl Cent Educ Stat                            National Center for Education Statistics 
 
Respir Med    Respiratory Medicine 
 
Ther Adv Chronic Dis  Therapeutic Advances in Chronic Disease 
 
World J Gastroenterol   World Journal of Gastroenterology 
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